• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Tuesday's Intraday Session

    4/30/24 12:31:18 PM ET
    $AKLI
    $ANVS
    $BRNS
    $CYCC
    Medical/Dental Instruments
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $AKLI alert in real time by email

    Gainers

    • Akili (NASDAQ:AKLI) stock moved upwards by 70.1% to $0.4 during Tuesday's regular session. The company's market cap stands at $31.4 million.
    • Cyclacel Pharmaceuticals (NASDAQ:CYCC) stock rose 51.83% to $2.06. The company's market cap stands at $2.7 million.
    • Eliem Therapeutics (NASDAQ:ELYM) shares rose 50.0% to $7.53. The company's market cap stands at $208.7 million.
    • GeneDx Hldgs (NASDAQ:WGS) stock moved upwards by 45.99% to $16.06. The market value of their outstanding shares is at $418.4 million. The company's, Q1 earnings came out yesterday.
    • Dare Bioscience (NASDAQ:DARE) stock moved upwards by 22.75% to $0.35. The company's market cap stands at $34.8 million.
    • Lucid Diagnostics (NASDAQ:LUCD) shares moved upwards by 20.7% to $0.91. The market value of their outstanding shares is at $43.7 million.

    Losers

    • NRX Pharmaceuticals (NASDAQ:NRXP) shares decreased by 23.9% to $2.7 during Tuesday's regular session. The market value of their outstanding shares is at $28.3 million.
    • Innovative Eyewear (NASDAQ:LUCY) stock decreased by 18.64% to $0.2. The company's market cap stands at $2.5 million.
    • Vaxxinity (NASDAQ:VAXX) shares declined by 17.66% to $0.13. The market value of their outstanding shares is at $16.0 million.
    • Barinthus Biotherapeutics (NASDAQ:BRNS) stock decreased by 16.99% to $2.15. The market value of their outstanding shares is at $83.6 million.
    • Annovis Bio (NYSE:ANVS) stock decreased by 16.83% to $6.05. The market value of their outstanding shares is at $66.7 million.
    • OpGen (NASDAQ:OPGN) shares declined by 15.87% to $0.45. The company's market cap stands at $5.4 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $AKLI alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AKLI
    $ANVS
    $BRNS
    $CYCC

    CompanyDatePrice TargetRatingAnalyst
    GeneDx Holdings Corp.
    $WGS
    2/9/2026$155.00Equal Weight → Overweight
    Wells Fargo
    GeneDx Holdings Corp.
    $WGS
    10/20/2025$155.00Buy
    Canaccord Genuity
    NRX Pharmaceuticals Inc.
    $NRXP
    9/8/2025$40.00Buy
    H.C. Wainwright
    GeneDx Holdings Corp.
    $WGS
    7/9/2025$110.00Overweight
    Piper Sandler
    GeneDx Holdings Corp.
    $WGS
    5/15/2025$88.00Buy
    Guggenheim
    GeneDx Holdings Corp.
    $WGS
    5/9/2025$80.00Hold → Buy
    Jefferies
    NRX Pharmaceuticals Inc.
    $NRXP
    4/2/2025$18.00Buy
    BTIG Research
    Annovis Bio Inc.
    $ANVS
    2/10/2025Buy → Hold
    D. Boral Capital
    More analyst ratings

    $AKLI
    $ANVS
    $BRNS
    $CYCC
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    CHIEF EXECUTIVE OFFICER Stueland Katherine sold $1,319,291 worth of shares (17,179 units at $76.80) and converted options into 30,671 shares, increasing direct ownership by 30% to 58,447 units (SEC Form 4)

    4 - GeneDx Holdings Corp. (0001818331) (Issuer)

    3/17/26 6:40:58 PM ET
    $WGS
    Retail: Computer Software & Peripheral Equipment
    Technology

    CHIEF FINANCIAL OFFICER Feeley Kevin converted options into 11,012 shares and sold $438,203 worth of shares (5,706 units at $76.80), increasing direct ownership by 24% to 27,148 units (SEC Form 4)

    4 - GeneDx Holdings Corp. (0001818331) (Issuer)

    3/17/26 6:39:59 PM ET
    $WGS
    Retail: Computer Software & Peripheral Equipment
    Technology

    SEC Form 4 filed by GeneDx Holdings Corp.

    4 - GeneDx Holdings Corp. (0001818331) (Issuer)

    3/11/26 4:28:48 PM ET
    $WGS
    Retail: Computer Software & Peripheral Equipment
    Technology

    $AKLI
    $ANVS
    $BRNS
    $CYCC
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    GeneDx upgraded by Wells Fargo with a new price target

    Wells Fargo upgraded GeneDx from Equal Weight to Overweight and set a new price target of $155.00

    2/9/26 6:58:22 AM ET
    $WGS
    Retail: Computer Software & Peripheral Equipment
    Technology

    Canaccord Genuity initiated coverage on GeneDx with a new price target

    Canaccord Genuity initiated coverage of GeneDx with a rating of Buy and set a new price target of $155.00

    10/20/25 8:45:12 AM ET
    $WGS
    Retail: Computer Software & Peripheral Equipment
    Technology

    H.C. Wainwright initiated coverage on NRx Pharmaceuticals with a new price target

    H.C. Wainwright initiated coverage of NRx Pharmaceuticals with a rating of Buy and set a new price target of $40.00

    9/8/25 8:58:39 AM ET
    $NRXP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AKLI
    $ANVS
    $BRNS
    $CYCC
    SEC Filings

    View All

    Dare Bioscience Inc. filed SEC Form 8-K: Unregistered Sales of Equity Securities

    8-K - Dare Bioscience, Inc. (0001401914) (Filer)

    3/17/26 4:37:30 PM ET
    $DARE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Annovis Bio Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - Annovis Bio, Inc. (0001477845) (Filer)

    3/16/26 5:06:04 PM ET
    $ANVS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-K filed by Annovis Bio Inc.

    10-K - Annovis Bio, Inc. (0001477845) (Filer)

    3/13/26 5:15:44 PM ET
    $ANVS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AKLI
    $ANVS
    $BRNS
    $CYCC
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    NeuroRPM to Deploy AI-Enabled Digital Biomarker Monitoring for Annovis Bio's Parkinson's Disease Clinical Trial

    WASHINGTON, D.C., March 19, 2026 (GLOBE NEWSWIRE) -- NeuroRPM, a digital health company focused on Parkinson's disease monitoring, today announced that its FDA-cleared wearable platform will be used for digital biomarker monitoring in Annovis Bio's ANVS-25002 open-label Parkinson's disease clinical trial. NeuroRPM's platform uses the Apple Watch to passively collect and analyze movement data during daily activities, providing continuous measurement of key Parkinson's motor symptoms. The ANVS-25002 study is expected to enroll approximately 500 participants with Parkinson's disease across multiple clinical sites. Eligible participants may choose to take part in the NeuroRPM digital monitori

    3/19/26 7:30:00 AM ET
    $ANVS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Annovis Partners with NeuroRPM to Deploy AI-Powered Digital Biomarker Technology in Parkinson's Disease Study

    MALVERN, Pa., March 19, 2026 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE:ANVS) ("Annovis" or the "Company"), a Phase 3 clinical-stage biotechnology company developing the investigational oral therapy, buntanetap, for neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD), today announced a partnership with NeuroRPM, a digital health technology company, to implement a new FDA-cleared artificial intelligence (AI) platform that collects movement data for symptom and disease management in its ongoing Parkinson's study. Annovis' recently launched open-label study in PD patients (ANVS-25002) is currently enrolling participants across the 25 sites in the United

    3/19/26 7:30:00 AM ET
    $ANVS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) to Report Full Year 2025 Financial Results and Provide a Corporate Update on March 24, 2026

    WILMINGTON, Del., March 19, 2026 (GLOBE NEWSWIRE) -- NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) ("NRx Pharmaceuticals", the "Company"), a clinical-stage biopharmaceutical company, today announced that it will host a conference call at 8:00am ET on Tuesday, March 24, 2026. In addition to reviewing the Company's financial results for the fiscal year ended December 31, 2025, the Company will provide an update on the significant progress achieved across its drug development programs and the HOPE Therapeutics clinical network, milestones that bring the Company closer to its founding mission of preventing suicide and transforming the treatment of depression and PTSD to improve the lives of patient

    3/19/26 7:00:00 AM ET
    $NRXP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AKLI
    $ANVS
    $BRNS
    $CYCC
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    $AKLI
    $ANVS
    $BRNS
    $CYCC
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    FDA Approval for XACIATO issued to DARE BIOSCIENCE INC

    Submission status for DARE BIOSCIENCE INC's drug XACIATO (ORIG-1) with active ingredient CLINDAMYCIN PHOSPHATE has changed to 'Approval' on 12/07/2021. Application Category: NDA, Application Number: 215650, Application Classification: Type 5 - New Formulation or New Manufacturer

    12/7/21 12:35:25 PM ET
    $DARE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Meister Keith A. bought $13,460,090 worth of shares (169,521 units at $79.40) (SEC Form 4)

    4 - GeneDx Holdings Corp. (0001818331) (Issuer)

    3/5/26 7:19:34 PM ET
    $WGS
    Retail: Computer Software & Peripheral Equipment
    Technology

    Chief Executive Officer Gross Harrison R. bought $1,980 worth of shares (1,500 units at $1.32), increasing direct ownership by 12% to 13,733 units (SEC Form 4)

    4 - Innovative Eyewear Inc (0001808377) (Issuer)

    1/22/26 11:29:05 AM ET
    $LUCY
    Ophthalmic Goods
    Health Care

    Chief Financial Officer Gayle Oswald bought $1,669 worth of shares (1,000 units at $1.67), increasing direct ownership by 54% to 2,865 units (SEC Form 4)

    4 - Innovative Eyewear Inc (0001808377) (Issuer)

    1/15/26 5:00:07 PM ET
    $LUCY
    Ophthalmic Goods
    Health Care

    $AKLI
    $ANVS
    $BRNS
    $CYCC
    Leadership Updates

    Live Leadership Updates

    View All

    NRx Pharmaceuticals (Nasdaq: NRXP) Appoints Prof. Joshua Brown MD, PhD, as Chief Medical Innovation Officer

    Prof. Brown is a pioneer in Transcranial Magnetic Stimulation (TMS) and serves as current President of the Clinical TMS Society and Editor-in-Chief of the Transcranial Magnetic Stimulation journal.Extensive publication history in the science of neuroplasticity and its relationship to healing depression and PTSD.Unique background in charting a path for forward deployment of TMS with neuroplastic medication to treat depression and PTSD in military personnel, veterans, and first responders. WILMINGTON, Del., March 02, 2026 (GLOBE NEWSWIRE) -- NRx Pharmaceuticals, Inc. (NASDAQ:NRXP), a clinical-stage biopharmaceutical company, today announced that it has appointed Prof. Joshua C. Brown, MD, P

    3/2/26 7:00:00 AM ET
    $NRXP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    GeneDx Appoints Dr. Linda Genen as Chief Medical Officer to Accelerate the Future of Genomic-First Care

    Recognized neonatologist and payer-strategy leader joins GeneDx to expand earlier diagnosis and establish genomics as a standard of care across healthcare GeneDx (NASDAQ:WGS), a leader in delivering improved health outcomes through genomic insights today announced Linda Genen, MD, MPH as Chief Medical Officer to further strengthen the company's commitment to delivering earlier answers and better outcomes for families through genomic insights. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260106493899/en/GeneDx Names Dr. Linda Genen, MD, MPH as Chief Medical Officer In her role at GeneDx, Dr. Genen will oversee Medical and Cli

    1/6/26 8:30:00 AM ET
    $WGS
    Retail: Computer Software & Peripheral Equipment
    Technology

    Annovis Provides Corporate Updates and Reports Third Quarter 2025 Financial Results

    MALVERN, Pa., Nov. 12, 2025 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE:ANVS) ("Annovis" or the "Company"), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD), today provided corporate updates and third quarter 2025 financial results. "The past quarter delivered breakthrough progress on every front," said Maria Maccecchini, Ph.D., President and CEO of Annovis. "Our pivotal Phase 3 Alzheimer's study has achieved full activation across all clinical sites, with enrollment momentum advancing every day. We have fortified our intellectual property position by transferring al

    11/12/25 8:00:00 AM ET
    $ANVS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AKLI
    $ANVS
    $BRNS
    $CYCC
    Financials

    Live finance-specific insights

    View All

    NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) to Report Full Year 2025 Financial Results and Provide a Corporate Update on March 24, 2026

    WILMINGTON, Del., March 19, 2026 (GLOBE NEWSWIRE) -- NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) ("NRx Pharmaceuticals", the "Company"), a clinical-stage biopharmaceutical company, today announced that it will host a conference call at 8:00am ET on Tuesday, March 24, 2026. In addition to reviewing the Company's financial results for the fiscal year ended December 31, 2025, the Company will provide an update on the significant progress achieved across its drug development programs and the HOPE Therapeutics clinical network, milestones that bring the Company closer to its founding mission of preventing suicide and transforming the treatment of depression and PTSD to improve the lives of patient

    3/19/26 7:00:00 AM ET
    $NRXP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    PAVmed to Hold Fourth Quarter and Full Year 2025 Business Update Conference Call and Webcast on March 30, 2026

    Conference Call and Webcast at 8:30 AM ETNEW YORK, March 16, 2026 /PRNewswire/ -- PAVmed Inc. (NASDAQ:PAVM) ("PAVmed" or the "Company"), a diversified commercial-stage medical technology company, operating in the medical device, diagnostics, and digital health sectors, today announced that it will host a business update conference call and webcast on Monday, March 30, 2026, at 8:30 AM ET. During the call, Lishan Aklog, M.D., PAVmed's Chairman and Chief Executive Officer, will provide a business update and discuss the Company's operations and growth strategy. In addition, Dennis McGrath, PAVmed's President and Chief Financial Officer, will discuss the Company's fourth quarter 2025 financial r

    3/16/26 9:01:00 AM ET
    $LUCD
    $PAVM
    Medical/Dental Instruments
    Health Care

    Barinthus Bio Reports Full Year 2025 Financial Results and Updates on Corporate Developments

    Proposed combination with Clywedog Therapeutics Inc. ("Clywedog") to create a differentiated company focusing on clinical metabolic and autoimmune pipeline assets and to build on the Company's base of high caliber institutional investors, expected to complete in the second quarter of 2026Multiple ascending dose part of the Phase 1 AVALON trial of VTP-1000 in celiac disease patients is progressing; data expected in the second half of 2026 GERMANTOWN, Md., March 13, 2026 (GLOBE NEWSWIRE) -- Barinthus Biotherapeutics plc (NASDAQ:BRNS) ("Barinthus Bio," or the "Company"), today announced its financial results for the year ended December 31, 2025, and provided an overview of the Company's co

    3/13/26 8:00:00 AM ET
    $BRNS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AKLI
    $ANVS
    $BRNS
    $CYCC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Lucid Diagnostics Inc.

    SC 13D/A - Lucid Diagnostics Inc. (0001799011) (Subject)

    12/12/24 4:30:32 PM ET
    $LUCD
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SC 13D/A filed by GeneDx Holdings Corp.

    SC 13D/A - GeneDx Holdings Corp. (0001818331) (Subject)

    11/20/24 9:36:13 PM ET
    $WGS
    Retail: Computer Software & Peripheral Equipment
    Technology

    Amendment: SEC Form SC 13D/A filed by GeneDx Holdings Corp.

    SC 13D/A - GeneDx Holdings Corp. (0001818331) (Subject)

    11/19/24 8:00:24 PM ET
    $WGS
    Retail: Computer Software & Peripheral Equipment
    Technology